FDA Study Suggesting 75 Percent Higher Risk of Blood Clots with Yaz
According to new study results conducted by the FDA, patients taking Yaz and Yasmin have a 75 percent higher risk of suffering from blood clots than people taking non-drospirinone-based birth control pills.
Recently, the FDA released a new drug safety report focused on the controversial oral contraceptives Yaz and Yasmin. While the study also looked at other pills whose primary ingredient is drospirenone (which is a synthetic progestin), Yaz and Yasmin were a primary focus of the study. What they learned during that study was that drospirenone-based pills represent a definite increase in risk for blood clots that can lead to potentially fatal conditions including heart attacks, strokes and pulmonary embolisms.
This particular FDA study analyzed data collected from 800,000 women between the years 2001 and 2007. The study included researchers from the FDA, Kaiser Permanente, Vanderbilt University and the University of Washington, who together discovered the 75 percent increased risk over the other birth control pills that use levonorgestrel instead. The study also found out that drospirenone doubled the risk of arterial thrombotic events (ATE) in new patients. More significantly, the study showed that those side effects occurred within the first three months of taking Yaz or Yasmin.
This will certainly help boost the claims from thousands of Yaz lawsuit plaintiffs who claim that they developed blood clots after taking Yaz or Yasmin. Most of those women are claiming that the makers of Yaz and Yasmin didn’t properly warn them that they could develop these life-threatening conditions associated with the pills. Bayer has stubbornly stood by the pills, claiming that its own study reveals that drospiranone-based pills are no more dangerous than other birth control pills. This new FDA study may finally put the matter to rest and provide the information necessary to get the pills recalled.
